Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx

<b>Supplementary Tables</b>. Co-stimulatory and co-inhibitory immune
markers in solid tumors with MET alterations.

<b>Background</b>
The
implication of MET alterations in solid tumors and the immune
microenvironment remains elusive.
<b>Materials
&amp; Methods</b>
FFPE
samples of 21 patients with solid tumors harboring MET alterations were used
for IHC staining. Extracted RNA was analyzed with the NanoString nCounter
human PanCancer Immune Profiling Panel.
<b>Results</b>
Patients
were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or
colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14
splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG,
XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed
in MET-altered cancers.
<b>Conclusion</b>

MET alterations may have a role in various solid
tumors as potential therapeutic targets and combination therapy candidates with
immune checkpoint inhibitors.